1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTissue Engineering & Regenerative Medicine Research Program is sponsored by National Institute of Dental and Craniofacial Research (NIDCR), NIH. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
DOC Regenerative Medicine Program | NIDCR DOC Regenerative Medicine Program The Dental, Oral, and Craniofacial (DOC) Regenerative Medicine Program supports basic and translational research employing interdisciplinary approaches for the reconstruction, repair, and regeneration of DOC tissues that have become impaired by disease or injury.
A goal of this program is to advance engineering of biocompatible DOC tissue constructs (e.g., bone, cartilage, ligament, skeletal muscle, blood vessels, and nerves of the craniofacial complex, teeth, oral mucosa, and salivary glands), and to support their functional integration into the host tissue microenvironment. The program also supports research efforts aimed at healing and regeneration of endogenous host tissues.
Example project topics may include (but are not limited to): Engineering multi-component tissue constructs that mimic the structure and function of native oral and craniofacial tissues Advancing functional integration of engineered DOC tissues into native host tissue Development of new scaffold fabrication techniques (e.g., 3D printing) or in situ functionality (e.g., smart or stimuli-responsive materials) to improve physiological relevance, efficacy, translational promise, or durability in regenerative applications Advancing the use of adult stem cells (either transplanted or manipulated within host tissues) to improve DOC host tissue healing or regeneration Performing mechanistic studies of DOC tissue damage (such as that caused by congenital defects, injury, or chronic disease) with the goal of developing pathways to reconstruct, repair, or regenerate these damaged tissues Testing of tissue engineering/regenerative medicine advancements in either established or newly developed models (including in vitro , in silico , or in vivo ) that exhibit demonstrable relevance to the human condition Previously Funded Grants (NIH RePORTER) DOC Regenerative Medicine Program
According to the current listing, eligibility includes: Universities, non‑profit research institutions, hospitals (subject to NIH eligibility). Confirm the full requirements in the official notice before applying.
Tissue Engineering & Regenerative Medicine Research Program is funded by National Institute of Dental and Craniofacial Research (NIDCR), NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article